Eval GRADE ECA CATT-Ranibizumab vs Bevazizumab para DMAE

Eval GRADE ECA CATT: Ranibizumab vs Bevacizumab para degeneración macular neovascular asociada a la edad. [Martin et al, 2011]

Grupo Evalmed

DESCARGAR PDF:

Eval GRADE ECA CATT 1y, ranibizumab vs bevacizumab, DMAE